T1	intervention 21 70	docetaxel and cyclophosphamide six- cycle therapy
T2	ethinicity 100 108	Japanese
T3	eligibility 109 181	human epidermal growth factor receptor 2-negative breast cancer patients
T4	outcome-Measure 587 595	toxicity
T6	intervention-participants 729 731	22
T7	control-participants 736 738	21
T8	outcome 798 833	grade 3 or higher adverse reactions
T9	outcome 843 878	neutropenia and febrile neutropenia
T10	outcome 1079 1104	treatment completion rate
T11	iv-bin-percent 1109 1114	86.4%
T12	iv-bin-percent 1164 1169	93.2%
T13	cv-bin-percent 1197 1202	95.2%
T14	cv-bin-percent 1207 1212	98.9%
T5	outcome-Measure 622 647	treatment completion rate
T15	outcome-Measure 652 675	relative dose intensity
T16	control 357 362	T-FEC
